



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Nancy D. HANSON et al.) Group Art Unit: 1655
Serial No.: 09/814,252) Examiner: unknown
Confirmation No.: 6198)
Filed: March 21, 2001) Docket No.: 180.0003 0103
For: PRIMERS FOR USE IN DETECTING BETA-LACTAMASES)

RECEIVED
AUG 20 2001
TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):


- ☒ **Small entity status is entitled to be asserted in the above-identified application.**
☒ An itemized return postcard.
☐ A Petition for Extension of Time for __ month(s) and a check in the amount of \$__ for the required fee.
☒ An Information Disclosure Statement (2 pgs); copy of 1 application; 1449 forms (7 pgs); and copies of 2 documents cited on the 1449 forms.
☐ A check in the amount of \$__, representing ____.
☐ A certified copy of a __ application, Serial No. __, filed _____, the right of priority of which is claimed under 35 U.S.C. §119.
☐ Other: ____.
☐ Amendment ☐ No Additional fee is required. ☐ The fee has been calculated as shown:

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$9 =	
Independent Claims				x \$40 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add \$135 Here →					
Total Additional Claim Fees Required					

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Transmittal Letter and the paper(s), as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on this 14 day of August, 2001.

MUETING, RAASCH & GEBHARDT, P.A.
Customer Number: 26813

By: 
Name: Ann M. Mueting
Reg. No.: 33,977
Direct Dial: 612-305-1217
Facsimile: 612-305-1228

(SMALL ENTITY TRANSMITTAL UNDER RULE 1.8)



#8 Aug-21-9

PATENT
Docket No. 180.0003 0103

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Nancy D. HANSON et al.) Group Art Unit: 1655
Serial No.: 09/814,252) Examiner: unknown
Confirmation No.: 6198)
Filed: March 21, 2001)
For: PRIMERS FOR USE IN DETECTING BETA-LACTAMASES)

RECEIVED

AUG 20 2001

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington D.C. 20231

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 forms, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

This is a divisional of U.S. Patent Application Serial No. 09/407,818 issued as U.S. Patent No.6,242,223 B1. In accordance with 37 C.F.R. §1.98(d), copies of documents previously cited by or submitted to the U.S. Patent Office in connection with Applicants' prior U.S. Patent No. 6,242,223 B1 (issued June 5, 2001), are not included herewith.

The Examiner's attention is directed to Sanders et al., "New Service Notification." This document was distributed no earlier than September 28, 1997, by the Center for Research in Anti-Infectives and Biotechnology, Creighton University School of Medicine. Subsequently, on or about December 4, 1997, the Center for Research in Anti-Infectives and Biotechnology at Creighton University, with which the inventors are associated, performed the service on at least 10 clinical isolates.

Information Disclosure StatementApplicant(s): *Nancy D. HANSON et al.*

Serial No.: 09/814,252

Confirmation No.: 6198

Filed: March 21, 2001

For: PRIMERS FOR USE IN DETECTING BETA-LACTAMASES

Page 2 of 2

RECEIVED

AUG 20 2001

TECH CENTER 1600/2900

Applicants also wish to bring the Examiner's attention to the following pending U.S. Application, as well as any prior art and any provisional U.S. patent applications referenced therein. A copy of the below-listed pending U.S. Patent Application is provided herewith.

List of Pending Non-Published U.S. Patent Applications


Applicant(s)	Application Number	Filing Date	Serial Nos. of Provisional Applications to which listed Application claims priority
Nancy D. Hanson et al.	09/814,257	03/21/01	60/102,181 60/121,765

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.8:


The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on this 14 day of August, 2001.


Ann M. Mueting

August 14, 2001
Date

AMM:lmg

Respectfully submitted,
Nancy D. Hanson et al.
By Representatives,
Mueting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Phone: (612)305-1220
Facsimile: (612)305-1228
Customer Number 26813

By: 
Ann M. Mueting
Reg. No. 33,977
Direct Dial (612)305-1217